China GDP beats street, weakness in manufacturing

Published 19-OCT-2015 16:01 P.M.

|

1 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The hard landing isn’t quite here yet if the numbers are to believed, with an annual growth rate to China’s GDP of 6.9% beating the street – however the figure is the lowest on record since early 2009 and there’s a slowdown in the manufacturing sector.

The National Bureau of Statistics released its numbers today, saying that the first three quarters of the year had delivered an overall growth figure of 6.9% from last year.

The first quarter was 7%, the second was 7%, and the third came in at 6.9% according to the official release.

A pre-release survey of economists conducted by Thompson Reuters had the figure at 6.8%, with a range between 6.4% to 7.2%.

While the official figure beat the consensus and the more bearish analysis out there, it means growth in China is at its lowest level since early 2009 – the height of the global financial crisis.

In mixed news for Australia, the level of industrial activity in the country went backward while the value of both imports and exports went down.

The NBS said that the output from industry showed growth of 6.2%, which was 0.1 percentage points lower than in the first half of the year.

In a separate release the Chinese government said total industrial production was up 5.7% year on year for September, lower than analyst estimates of 6%.

Meanwhile, the manufacturing sector grew by 7%.

An overarching goal to shift away from an export-based economy continued to gather pace, with the value of exports from the manufacturing sector down 1.1% year on year. Retail sales grew by 10.9%, ahead of the expected 10.8% growth.

Worryingly for Australia, the value of imports was 7,633.4 billion yuan, down by 15.1%.

The China middle class story also continued to gather pace, with national per capita disposable income up 7.7%, which was up 0.1 percentage points on the first half of the year.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X